16,008 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 16,008 shares of the medical device company's stock, valued at approximately $1,986,000.

Several other institutional investors have also recently added to or reduced their stakes in DXCM. Assetmark Inc. grew its stake in shares of DexCom by 7.3% during the 3rd quarter. Assetmark Inc. now owns 46,140 shares of the medical device company's stock valued at $4,305,000 after buying an additional 3,132 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in DexCom by 8.7% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 36,001 shares of the medical device company's stock worth $3,359,000 after acquiring an additional 2,874 shares during the last quarter. CIBC Asset Management Inc raised its holdings in shares of DexCom by 11.2% in the 3rd quarter. CIBC Asset Management Inc now owns 107,941 shares of the medical device company's stock worth $10,071,000 after purchasing an additional 10,844 shares during the period. Capital Insight Partners LLC lifted its stake in shares of DexCom by 10.4% in the 3rd quarter. Capital Insight Partners LLC now owns 2,296 shares of the medical device company's stock valued at $214,000 after purchasing an additional 216 shares in the last quarter. Finally, OPTIMAS CAPITAL Ltd purchased a new stake in shares of DexCom during the 3rd quarter worth about $1,390,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 1.7 %

DXCM stock traded down $2.10 during mid-day trading on Monday, hitting $124.95. 2,596,535 shares of the company were exchanged, compared to its average volume of 2,946,563. The company has a market capitalization of $49.69 billion, a PE ratio of 80.61, a price-to-earnings-growth ratio of 2.17 and a beta of 1.23. The firm has a fifty day simple moving average of $133.31 and a 200 day simple moving average of $122.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. On average, research analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the transaction, the chief operating officer now owns 273,913 shares of the company's stock, valued at $36,816,646.33. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the firm's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the transaction, the chief operating officer now owns 273,913 shares of the company's stock, valued at $36,816,646.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 190,004 shares of company stock worth $25,610,270. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DXCM shares. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Thursday. Citigroup lifted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the company a "buy" rating in a report on Friday, April 26th. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price objective on the stock. Finally, UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus price target of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.